Successful in vitro growth of human head and neck cancer after transplantation in nude mice

1985 ◽  
Vol 241 (3) ◽  
pp. 225-232
Author(s):  
Eduard C. M. Heinerman ◽  
Boudewijn J. M. Braakhuis ◽  
Gijs H. Boerrigter ◽  
Gordon B. Snow
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Nude Mice ◽  
Human Head ◽  
In Vitro Growth

PO-0942 EXPRESSION OF THE EGFR/HER2/PAKT PATHWAY IN VITRO AND IN VIVO IS AFFECTED BY HYPOXIA IN HUMAN HEAD AND NECK CANCER

2012 ◽  
Vol 103 ◽  
pp. S371
Author(s):  
J. Bussink ◽  
J.H.A.M. Kaanders ◽  
D.L. Wheeler ◽  
A.J. van der Kogel ◽  
M. Iida ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Human Head

scholarly journals The Cancer Stem Cell Concept in Progression of Head and Neck Cancer

2009 ◽  
Vol 2009 ◽  
pp. 1-8 ◽  
Author(s):  
Zhuo (Georgia) Chen
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Solid Tumors ◽  
Neck Cancer ◽  
Human Head ◽  
Short Review ◽  
Cancer Type ◽  
Progression Model

Human head and neck cancer (HNC) is a highly heterogeneous disease. Understanding the biology of HNC progression is necessary for the development of novel approaches to its prevention, early detection, and treatment. A current evolutional progression model has limitations in explaining the heterogeneity observed in a single tumor nest. Accumulating evidence supports the existence of cancer stem cells (CSCs) as small subpopulations in solid tumors, including HNC. These CSCs can be selected by appropriate cell surface markers, which are cancer type specific and have been confirmed by uniquein vitroandin vivoassays. Selected CSC populations maintain a self-renewal capability and show aggressive behaviors, such as chemoresistance and metastasis. In addition to introducing the CSC concept in solid tumors, this short review summarizes current publications in HNC CSC and the prospective development and application of the CSC concept to HNC in the clinic.

scholarly journals Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo

1998 ◽  
Vol 79 (1) ◽  
pp. 82-88 ◽  
Author(s):  
M J P Welters ◽  
A M J Fichtinger-Schepman ◽  
R A Baan ◽  
A J Jacobs-Bergmans ◽  
A Kegel ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Drug Sensitivity ◽  
Human Head ◽  
Dna Adduct ◽  
Platinum Content

Permanent in vitro growth is associated with poor prognosis in head and neck cancer

2004 ◽  
Vol 124 (2) ◽  
pp. 192-196 ◽  
Author(s):  
K. Pekkola ◽  
A. Räikkä ◽  
H. Joensuu ◽  
H. Minn ◽  
K. Aitasalo ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
In Vitro Growth

Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro

2006 ◽  
Vol 17 (4) ◽  
pp. 377-384 ◽  
Author(s):  
Jung-Won Lee ◽  
Jong-Kook Park ◽  
Sin-Hyung Lee ◽  
Seong-Yun Kim ◽  
Yong-Baik Cho ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Cells ◽  
Neck Cancer ◽  
Human Head ◽  
Anti Tumor Activity

Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice

Head & Neck ◽  
1989 ◽  
Vol 11 (6) ◽  
pp. 511-515 ◽  
Author(s):  
Boudewijn J. M. Braakhuis ◽  
Guus A. M. S. Van Dongen ◽  
Marian Bagnay ◽  
Marijke Van Walsum ◽  
Gordon B. Snow
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Nude Mice ◽  
Human Head ◽  
Athymic Nude Mice

scholarly journals Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice

1986 ◽  
Vol 54 (1) ◽  
pp. 53-59 ◽  
Author(s):  
G H Boerrigter ◽  
E C M Heinerman ◽  
B J M Braakhuis ◽  
G B Snow
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Nude Mice ◽  
Clonogenic Assay ◽  
Human Head

Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.

1989 ◽  
Vol 7 (6) ◽  
pp. 761-768 ◽  
Author(s):  
E E Vokes ◽  
W R Panje ◽  
R L Schilsky ◽  
R Mick ◽  
A M Awan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Local Therapy ◽  
Complete Response ◽  
Synergistic Activity ◽  
Dose Levels ◽  
Concomitant Radiotherapy

Hydroxyurea and fluorouracil (5-FU) are active cytotoxic drugs in head and neck cancer and have shown synergistic activity in vitro. Both drugs also act as radiosensitizers. Therefore, we administered radiotherapy at daily fractions of 180 to 200 cGy with simultaneous continuous infusion 5-FU at 800 mg/m2/d and escalating daily doses of hydroxyurea for five days. Cycles were repeated every other week until completion of radiotherapy. Thirty-nine inoperable patients were treated at six dose levels of hydroxyurea ranging from 500 mg to 3,000 mg orally daily. Little effect of hydroxyurea on the WBC or platelet count was noted in patients receiving less than 2,000 mg daily, whereas both parameters decreased progressively in patients receiving 2,000 mg daily or more. Mucositis occurred at all dose levels, requiring frequent dose reduction of 5-FU; however, in patients receiving a daily hydroxyurea dose of 2,000 mg or less, the median weekly 5-FU dose administered was 1,725 mg/m2 (86% of the intended 5-FU dose), whereas at daily hydroxyurea doses exceeding 2,000 mg, the median weekly 5-FU dose decreased to 1,133 mg/m2 (57%) (P = .001). Of 15 evaluable patients with recurrent disease after prior local therapy only one failed to respond; six had a complete response (CR), and eight a partial response (PR). Of 17 evaluable patients without prior local therapy, 12 had a CR, with no patient developing recurrence in the irradiated field to date; five patients had a PR. We conclude that the recommended dose of hydroxyurea in this regimen is 2,000 mg daily. That dose will cause mild to moderate myelosuppression and will allow for delivery of greater than 80% of the intended 5-FU dose. The activity of this regimen in poor-prognosis head and neck cancer exceeds 90%; its further investigation in previously untreated patients is warranted.

Sign in / Sign up

Export Citation Format

Share Document